Current challenges in the development of new treatments for lupus

Research output: Contribution to journalArticle

Standard

Current challenges in the development of new treatments for lupus. / Dall'Era, Maria; Bruce, Ian N; Gordon, Caroline; Manzi, Susan; McCaffrey, Janis; Lipsky, Peter.

In: Annals of the Rheumatic Diseases, Vol. 78, No. 6, 12.01.2019, p. 729-735.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Dall'Era, Maria ; Bruce, Ian N ; Gordon, Caroline ; Manzi, Susan ; McCaffrey, Janis ; Lipsky, Peter. / Current challenges in the development of new treatments for lupus. In: Annals of the Rheumatic Diseases. 2019 ; Vol. 78, No. 6. pp. 729-735.

Bibtex

@article{e1b4999f0c71414fad6bac1321da7be1,
title = "Current challenges in the development of new treatments for lupus",
abstract = "Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a considerable impact on patients' quality of life. Despite the plethora of clinical trials for SLE since the turn of the millennium, only one new treatment has been approved for the condition, and the overall pace of successful drug development remains slow. Nevertheless, the myriad of clinical studies has yielded insights that have informed and refined our understanding of eligibility criteria, outcome measures and trial design in SLE. In this review, we highlight the achievements of clinical trials as well as the major pitfalls that have been identified in drug development for SLE and, in doing so, identify areas where collaboration and consensus will be important to facilitate progress.",
keywords = "autoantibodies, autoimmune diseases, lupus nephritis, systemic lupus erythematosus",
author = "Maria Dall'Era and Bruce, {Ian N} and Caroline Gordon and Susan Manzi and Janis McCaffrey and Peter Lipsky",
year = "2019",
month = "1",
day = "12",
doi = "10.1136/annrheumdis-2018-214530",
language = "English",
volume = "78",
pages = "729--735",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "6",

}

RIS

TY - JOUR

T1 - Current challenges in the development of new treatments for lupus

AU - Dall'Era, Maria

AU - Bruce, Ian N

AU - Gordon, Caroline

AU - Manzi, Susan

AU - McCaffrey, Janis

AU - Lipsky, Peter

PY - 2019/1/12

Y1 - 2019/1/12

N2 - Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a considerable impact on patients' quality of life. Despite the plethora of clinical trials for SLE since the turn of the millennium, only one new treatment has been approved for the condition, and the overall pace of successful drug development remains slow. Nevertheless, the myriad of clinical studies has yielded insights that have informed and refined our understanding of eligibility criteria, outcome measures and trial design in SLE. In this review, we highlight the achievements of clinical trials as well as the major pitfalls that have been identified in drug development for SLE and, in doing so, identify areas where collaboration and consensus will be important to facilitate progress.

AB - Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a considerable impact on patients' quality of life. Despite the plethora of clinical trials for SLE since the turn of the millennium, only one new treatment has been approved for the condition, and the overall pace of successful drug development remains slow. Nevertheless, the myriad of clinical studies has yielded insights that have informed and refined our understanding of eligibility criteria, outcome measures and trial design in SLE. In this review, we highlight the achievements of clinical trials as well as the major pitfalls that have been identified in drug development for SLE and, in doing so, identify areas where collaboration and consensus will be important to facilitate progress.

KW - autoantibodies

KW - autoimmune diseases

KW - lupus nephritis

KW - systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=85059879870&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2018-214530

DO - 10.1136/annrheumdis-2018-214530

M3 - Article

VL - 78

SP - 729

EP - 735

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 6

ER -